Conditioning of either OCI-LY3 or primary CLL cells with pevonedistat, but not Bcl-2 inhibitor venetoclax, enhanced TRAIL-mediated caspase-8 activation (Figure 4A-4B). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.